Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: since Aug 17, 2026 (set the dates above to see older items)
Phase 3 studies marked completed, by completion date. Studies whose sponsor is matched to a public company. Change Sponsors to Everyone to include the rest.
| CompletedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later. | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | Enrolled | Results | Source |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis NCT07917507 · Plaque, Gingivitis 0.412% stannous fluoride toothpaste and flat trimmed toothb… | CL Colgate Palmolive | Phase 3 | 84 | — | Registry ↗ |
| Oct 29, 2026 | A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in… NCT05133531 · Paroxysmal Nocturnal Hemoglobinuria Ravulizumab, Pozelimab | REGN Regeneron Pharmaceuticals | Phase 3 | 202 | — | Registry ↗ |
| Oct 26, 2026 | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propiona… NCT06664619 · Asthma Fp/ABS, FP | TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | 649 | — | Registry ↗ |
| Oct 25, 2026 | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vacc… NCT07425392 · Pneumococcal Disease 31-valent pneumococcal conjugate vaccine, PCV20 | PCVX Vaxcyte, Inc. | Phase 3 | 752 | — | Registry ↗ |
| Oct 21, 2026 | A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza… NCT07365826 · Pneumococcal Disease 31-valent pneumococcal conjugate vaccine, Seasonal Influenz… | PCVX Vaxcyte, Inc. | Phase 3 | 1,390 | — | Registry ↗ |
| Oct 20, 2026 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the… NCT03036098 · Urothelial Cancer Nivolumab, Ipilimumab | BMY Bristol-Myers Squibb | Phase 3 | 1,314 | posted | Registry ↗ |
| Oct 14, 2026 | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects NCT05172726 · Plaque Psoriasis tapinarof cream, 1% | OGN Organon and Co | Phase 3 | 58 | — | Registry ↗ |
| Oct 9, 2026 | Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Yea… NCT02612454 · Atopic Dermatitis Dupilumab | REGN Regeneron Pharmaceuticals | Phase 3 | 880 | — | Registry ↗ |
| Sep 28, 2026 | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab… NCT06768671 · Hidradenitis Suppurativa Sonelokimab | MLTX MoonLake Immunotherapeutics AG | Phase 3 | 35 | — | Registry ↗ |
| Sep 24, 2026 | Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine… NCT07135986 · Meningococcal Infection, Healthy Volunteers MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine | SNY Sanofi | Phase 3 | 1,602 | — | Registry ↗ |
| Sep 22, 2026 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age NCT07300839 · COVID-19, SARS-COV-2 Infection BNT162b2 Vaccine, Placebo | BNTX BioNTech SE | Phase 3 | 5,240 | — | Registry ↗ |
| Sep 22, 2026 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (… NCT04129502 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) TAK-788, Pemetrexed | TAK Takeda | Phase 3 | 354 | — | Registry ↗ |
| Sep 21, 2026 | Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on… NCT06750289 · Eosinophilic Asthma ICS-LABA, benralizumab | AZN AstraZeneca | Phase 3 | 130 | — | Registry ↗ |
| Sep 17, 2026 | Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adult… NCT07284654 · Pneumococcal Disease 31 valent pneumococcal conjugate vaccine, PCV20 | PCVX Vaxcyte, Inc. | Phase 3 | 4,049 | — | Registry ↗ |
| Sep 15, 2026 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle In… NCT06331299 · Bladder Cancer, Urothelial Carcinoma UGN-103 | URGN UroGen Pharma Ltd. | Phase 3 | 99 | posted | Registry ↗ |
| Sep 14, 2026 | Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults… NCT06050122 · Gorlin Syndrome Patidegib Topical Gel, Patidegib Topical Gel with no active… | SLGL Sol-Gel Technologies, Ltd. | Phase 3 | 113 | — | Registry ↗ |
| Sep 14, 2026 | Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Withou… NCT03754790 · Hemophilia Fitusiran | SNY Genzyme, a Sanofi Company | Phase 3 | 281 | — | Registry ↗ |
| Sep 10, 2026 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia NCT06347016 · Severe Hypertriglyceridemia Plozasiran Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | 311 | — | Registry ↗ |
| Sep 10, 2026 | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD NCT06208306 · Chronic Obstructive Pulmonary Disease Itepekimab (SAR440340), Placebo | SNY Sanofi | Phase 3 | 669 | — | Registry ↗ |
| Sep 9, 2026 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV NCT06868264 · HEPATITIS C VIRUS CHRONIC INFECTION Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (S… | AVIR Atea Pharmaceuticals, Inc. | Phase 3 | 940 | — | Registry ↗ |
| Sep 9, 2026 | 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Ca… NCT04689828 · Prostatic Neoplasms 177Lu-PSMA-617, 68Ga-PSMA-11 | NVS Novartis Pharmaceuticals | Phase 3 | 469 | posted | Registry ↗ |
| Sep 8, 2026 | Study of Bitopertin in Participants With EPP or XLP (APOLLO) NCT06910358 · Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyri… Placebo, DISC-1459 | IRON Disc Medicine, Inc | Phase 3 | 183 | — | Registry ↗ |
| Sep 8, 2026 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia NCT06347133 · Hypertriglyceridemia Plozasiran Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | 1,456 | — | Registry ↗ |
| Sep 7, 2026 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Mu… NCT03992430 · Muscular Dystrophy, Duchenne Eteplirsen | SRPT Sarepta Therapeutics, Inc. | Phase 3 | 160 | — | Registry ↗ |
| Sep 4, 2026 | A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Ace… NCT07596173 · Diphtheria-Tetanus-acellular Pertussis Vaccines dTpa vaccine | GSK GlaxoSmithKline | Phase 3 | 90 | — | Registry ↗ |
| Sep 4, 2026 | Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) NCT04652882 · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm Tasimelteon, Placebo | VNDA Vanda Pharmaceuticals | Phase 3 | 43 | — | Registry ↗ |
| Sep 3, 2026 | A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration an… NCT07032597 · Mid Face Volume Deficit HArmonyCa Lidocaine Injectable Gel, Restylane® Perlane® Lid… | ABBV AbbVie | Phase 3 | 252 | — | Registry ↗ |
| Sep 3, 2026 | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Mod… NCT05565560 · Plaque Psoriasis Apremilast | AMGN Amgen | Phase 3 | 21 | — | Registry ↗ |
| Sep 2, 2026 | A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injection… NCT06687980 · Lichen Simplex Chronicus Dupilumab, Placebo | SNY Sanofi | Phase 3 | 138 | — | Registry ↗ |
| Aug 31, 2026 | A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injection… NCT06687967 · Lichen Simplex Chronicus Dupilumab, Placebo | SNY Sanofi | Phase 3 | 142 | — | Registry ↗ |
| Aug 28, 2026 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy,… NCT05568095 · Advanced Upper Gastrointestinal Tract Adenocarcinoma Domvanalimab, Zimberelimab | RCUS Arcus Biosciences, Inc. | Phase 3 | 1,040 | — | Registry ↗ |
| Aug 25, 2026 | A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Sev… NCT07543380 · Respiratory Syncytial Virus (RSV) RSVpreF | PFE Pfizer | Phase 3 | 130 | — | Registry ↗ |
| Aug 25, 2026 | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia NCT06347003 · Severe Hypertriglyceridemia Plozasiran Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | 446 | — | Registry ↗ |
| Aug 24, 2026 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administer… NCT04956692 · Non-Small Cell Lung Cancer Pembrolizumab SC, Pembrolizumab IV | MRK Merck Sharp & Dohme LLC | Phase 3 | 531 | posted | Registry ↗ |
| Aug 21, 2026 | A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-… NCT07284381 · Dry Eye Disease ABBV-444, REFRESH OPTIVE UD | ABBV AbbVie | Phase 3 | 261 | — | Registry ↗ |
| Aug 20, 2026 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to… NCT05643534 · Irritable Bowel Syndrome With Constipation (IBS-C) Tenapanor 50 MG, Tenapanor 25 mg bid | ARDX Ardelyx | Phase 3 | 180 | — | Registry ↗ |
| Aug 19, 2026 | A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy NCT03762850 · Immunoglobulin A Nephropathy sparsentan, irbesartan | TVTX Travere Therapeutics, Inc. | Phase 3 | 406 | posted | Registry ↗ |
| Aug 17, 2026 | A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome… NCT06104124 · Sjogren's Syndrome Dazodalibep, Placebo | AMGN Amgen | Phase 3 | 651 | — | Registry ↗ |
The newest 38 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 3:15 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances